A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).
Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Olivia Robin McKennan(Kettering University), Travis E. Adamson(Memorial Sloan Kettering Cancer Center), Moriah Martindale(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Li‐Xuan Qin(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Joseph P. Erinjeri(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Robert A. Lefkowitz(Memorial Sloan Kettering Cancer Center), Sujana Movva(Memorial Sloan Kettering Cancer Center), Mary Louise Keohan(Roche (Switzerland)), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Jason E. Chan(Memorial Sloan Kettering Cancer Center), Viswatej Avutu(Memorial Sloan Kettering Cancer Center)
Cited by 6
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733